Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-70
SponsorJens Titze

About this trial

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.

Eligibility criteria

Qualifiers

Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.

Male and female patients older than 21 years.

Willingness to participate and ability to provide informed consent.

Disqualifiers

implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)

iron-based tattoos

any other pieces of metal or devices that are not MR-Safe anywhere in the body

patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner

Trial design

Treatments tested in this trial

  • 23NaMRI Scan
  • Potassium Chloride (KCl)

Treatment groups

80 Participants
are divided into 1 treatment group

Sponsors and collaborators

Jens Titze

Lead sponsor

Duke-NUS Graduate Medical School

Sponsor institution

Changi General Hospital

Collaborator

Singapore General Hospital

Collaborator

Sengkang General Hospital

Collaborator